JP2022531980A5 - - Google Patents
Info
- Publication number
- JP2022531980A5 JP2022531980A5 JP2021567974A JP2021567974A JP2022531980A5 JP 2022531980 A5 JP2022531980 A5 JP 2022531980A5 JP 2021567974 A JP2021567974 A JP 2021567974A JP 2021567974 A JP2021567974 A JP 2021567974A JP 2022531980 A5 JP2022531980 A5 JP 2022531980A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025060710A JP2025118606A (ja) | 2019-05-14 | 2025-04-01 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847605P | 2019-05-14 | 2019-05-14 | |
| US62/847,605 | 2019-05-14 | ||
| PCT/IB2020/054594 WO2020230091A1 (en) | 2019-05-14 | 2020-05-14 | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025060710A Division JP2025118606A (ja) | 2019-05-14 | 2025-04-01 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531980A JP2022531980A (ja) | 2022-07-12 |
| JPWO2020230091A5 JPWO2020230091A5 (https=) | 2023-07-11 |
| JP2022531980A5 true JP2022531980A5 (https=) | 2023-07-11 |
Family
ID=78716450
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021567974A Pending JP2022531980A (ja) | 2019-05-14 | 2020-05-14 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法 |
| JP2025060710A Pending JP2025118606A (ja) | 2019-05-14 | 2025-04-01 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025060710A Pending JP2025118606A (ja) | 2019-05-14 | 2025-04-01 | 二重特異性抗ｅｇｆｒ／ｃ－ｍｅｔ抗体と第３世代ｅｇｆｒチロシンキナーゼ阻害剤との併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP3968985A4 (https=) |
| JP (2) | JP2022531980A (https=) |
| KR (1) | KR20220010731A (https=) |
| CN (1) | CN113840601A (https=) |
| AU (1) | AU2020275272A1 (https=) |
| BR (1) | BR112021022828A2 (https=) |
| CA (1) | CA3140360A1 (https=) |
| EA (1) | EA202193117A1 (https=) |
| IL (1) | IL287962A (https=) |
| MA (1) | MA55978A (https=) |
| MX (1) | MX2021013955A (https=) |
| SG (1) | SG11202112412QA (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024346227A1 (en) * | 2023-09-21 | 2026-04-09 | Beijing Neox Biotech Limited | Multi-specific antibodies and uses thereof |
| TW202519556A (zh) * | 2023-09-28 | 2025-05-16 | 大陸商上海翰森生物醫藥科技有限公司 | 雙特異性抗體在製備治療癌症的藥物中的用途 |
| CN120271706A (zh) * | 2023-12-29 | 2025-07-08 | 上海安领科生物医药有限公司 | 抗egfr单抗、其双特异性抗体、药物组合物和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| RU2601892C2 (ru) * | 2008-03-06 | 2016-11-10 | Дженентек, Инк. | Комбинированная терапия антагонистами с-мет и egfr |
| DK2560993T3 (da) * | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| CN113201073A (zh) * | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| US9695228B2 (en) * | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
| EP3929190B1 (en) * | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| AR111469A1 (es) * | 2017-04-21 | 2019-07-17 | Yuhan Corp | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma |
| SG11202108311RA (en) * | 2019-02-26 | 2021-09-29 | Janssen Biotech Inc | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
-
2020
- 2020-05-14 AU AU2020275272A patent/AU2020275272A1/en active Pending
- 2020-05-14 CA CA3140360A patent/CA3140360A1/en active Pending
- 2020-05-14 EP EP20806609.2A patent/EP3968985A4/en active Pending
- 2020-05-14 KR KR1020217040739A patent/KR20220010731A/ko active Pending
- 2020-05-14 SG SG11202112412QA patent/SG11202112412QA/en unknown
- 2020-05-14 CN CN202080035662.6A patent/CN113840601A/zh active Pending
- 2020-05-14 BR BR112021022828A patent/BR112021022828A2/pt unknown
- 2020-05-14 MX MX2021013955A patent/MX2021013955A/es unknown
- 2020-05-14 MA MA055978A patent/MA55978A/fr unknown
- 2020-05-14 EA EA202193117A patent/EA202193117A1/ru unknown
- 2020-05-14 JP JP2021567974A patent/JP2022531980A/ja active Pending
-
2021
- 2021-11-09 IL IL287962A patent/IL287962A/en unknown
-
2025
- 2025-04-01 JP JP2025060710A patent/JP2025118606A/ja active Pending